On May 6, 2024, Altimmune, Inc. was sued for violations of the federal securities laws in the United States District Court for the District of Maryland on behalf of investors who purchased or otherwise acquired Altimmune securities
between December 1, 2023 and April 26, 2024, both dates inclusive (the “Class Period”).
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.